Skip to main content
Erschienen in: Journal of Clinical Immunology 2/2013

01.01.2013

Overview of Routes of IgG Administration

verfasst von: Troy R. Torgerson

Erschienen in: Journal of Clinical Immunology | Sonderheft 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The use of exogenous serum to provide protection against infections began more than a century ago. Over time, this concept matured and led to the preparation of concentrated immunoglobulin (IgG) products that were safe and effective when delivered subcutaneously (SC) or intramuscularly (IM) but were not ideal for intravenous (IV) use. Continued improvements led to the development of IgG preparations that are safe for either subcutaneous IgG (SCIG) or intravenous IgG (IVIG) delivery and allow providers and patients significant flexibility to develop an effective but manageable treatment plan. Factors that influence the choice of IgG product and delivery method can maximize the therapeutic benefit and provide the best possible quality of life for patients.
Literatur
1.
Zurück zum Zitat Behring V. Uber das Zustandekommen der Diphterie–Immunitat und der Tetanus–Immunitat bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.CrossRef Behring V. Uber das Zustandekommen der Diphterie–Immunitat und der Tetanus–Immunitat bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.CrossRef
2.
Zurück zum Zitat Berger M. A history of immunoglobulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368–78.PubMedCrossRef Berger M. A history of immunoglobulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368–78.PubMedCrossRef
3.
Zurück zum Zitat Janeway CA. The development and clinical uses of immunoglobulins: a review. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington DC: National Academy of Sciences; 1970. p. 3–14. Janeway CA. The development and clinical uses of immunoglobulins: a review. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington DC: National Academy of Sciences; 1970. p. 3–14.
4.
5.
Zurück zum Zitat Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.PubMed Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.PubMed
6.
Zurück zum Zitat Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRef Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRef
Metadaten
Titel
Overview of Routes of IgG Administration
verfasst von
Troy R. Torgerson
Publikationsdatum
01.01.2013
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe Sonderheft 2/2013
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9845-2

Weitere Artikel der Sonderheft 2/2013

Journal of Clinical Immunology 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.